HFHernan Polo Friz

Hernan Polo Friz

*This is an algorithmically generated author record based on publicly available information.

Hernan Polo Friz has a total of 125 co-authors. Here are the top co-authors by number of shared publications:

  • Claudio Cimminiello

    Research and Study Center of the Italian Society of Angiology and Vascular Pathology (Società Italiana di Angiologia ePatologia Vascolare, SIAPAV) Milan Italy

    16 shared publications
  • Laura Primitz

    Internal Medicine, Medical Department, Vimercate Hospital, Azienda Socio Sanitaria Territoriale (ASST) della Brianza, Vimercate, Italy

    12 shared publications
  • Patrizia Boracchi

    Department of Biomedical and Clinical Sciences “L. Sacco”, University of Milan, Milan, Italy

    12 shared publications
  • Giuseppe Vighi

    Internal Medicine, Medical Department Vimercate Hospital, ASST di Vimercate Vimercate Italy

    7 shared publications
  • Michele Bombelli

    Internal Medicine, Medical Department, Desio Hospital, ASST della Brianza, Desio, Italy

    6 shared publications
  • Annalisa Orenti

    Department of Clinical Sciences and Community Health, Dipartimento di Eccellenza 2023-2027, Laboratory of Medical Statistics, Biometry and Epidemiology “G.A. Maccacaro”, University of Milan, Milan, Italy

    5 shared publications

Latest Publications

  • Machine learning and LACE index for predicting 30-day readmissions after heart failure hospitalization in elderly patients

    by Hernan Polo Friz, Valentina Esposito, Giuseppe Marano, Laura Primitz, Alice Bovio, Giovanni Delgrossi, Michele Bombelli, Guido Grignaffini, Giovanni Monza, Patrizia Boracchi

    Machine learning (ML) techniques may improve readmission prediction performance in heart failure (HF) patients. This study aimed to assess the ability of ML algorithms to predict unplanned all-cause 30-day readmissions in HF elderly patients, and to compare them with conventional LACE (Length of hospitalization, Acuity, Comorbidities, Emergency department visits) index. All patients aged ≥ 65 years discharged alive between 2010 and 2019 after a hospitalization for acute HF were included in this retrospective cohort study. We applied MICE (Multivariate Imputation via Chained Equations) method to obtain a balanced, fully valued dataset and LASSO (Least Absolute Shrinkage and Selection Operator) algorithm to get the most significant features. Training (80% of records) and test (20%) cohorts were randomly selected. Study population: 3079 patients, 394 (12.8%) presented at least one readmission within 30 days, and 2685 (87.2%) did not. In the test cohort AUCs (IC95%) of XGBoost, Ada Boost Classifier, Random forest, and Gradient Boosting, and LACE Index were: 0.803 (0.734–0.872), 0.782 (0.711–0.854), 0.776 (0.703–0.848), 0.786 (0.715–0.857), and 0.504 (0.414–0.594), respectively, for predicting readmissions. A SHAP analysis was performed to offer a breakdown of the ML variables associated with readmission. Positive and negative predicting values estimates of the different ML models and LACE index were also provided, for several values of readmission rate prevalence. Among elderly patients, the rate of all-cause unplanned 30-day readmissions after hospitalization due to an acute HF was high. ML models performed better than the conventional LACE index for predicting readmissions. ML models can be proposed as promising tools for the identification of subjects at high risk of hospitalization in this clinical setting, enabling care teams to target interventions for improving overall clinical outcomes.


  • Open Access

    Acute pulmonary embolism in patients presenting pulmonary deterioration after hospitalisation for non‐critical COVID‐19

    by Hernan Polo Friz, Elia Gelfi, Annalisa Orenti, Elena Motto, Laura Primitz, Tino Donzelli, Marcello Intotero, Paolo Scarpazza, Giuseppe Vighi, Claudio Cimminiello, et al.

    Background: Emerging evidence suggests an association between COVID‐19 and acute pulmonary embolism (APE).Aims: To assess the prevalence of APE in patients hospitalised for non‐critical COVID‐19 who presented clinical deterioration, and to investigate the association of clinical and biochemical variables with a confirmed diagnosis of APE in these subjects.Methods: All consecutive patients admitted to the internal medicine department of a general hospital with a diagnosis of non‐critical COVID‐19, who performed a computer tomography pulmonary angiography (CTPA) for respiratory deterioration in April 2020, were included in this retrospective cohort study.Results: Study populations: 41 subjects, median (interquartile range) age: 71.7 (63–76) years, CPTA confirmed APE = 8 (19.51%, 95% confidence interval (CI): 8.82–34.87%). Among patients with and without APE, no significant differences were found with regards symptoms, comorbidities, treatment, Wells score and outcomes. The optimal cut‐off value of d‐dimer for predicting APE was 2454 ng/mL, sensitivity (95% CI): 63 (24–91), specificity: 73 (54–87), positive predictive value: 36 (13–65), negative predictive value: 89 (71–98) and AUC: 0.62 (0.38–0.85). The standard and age‐adjusted d‐dimer cut‐offs, and the Wells score ≥2 did not associate with confirmed APE, albeit a cut‐off value of d‐dimer = 2454 ng/mL showed an relative risk: 3.21; 95% CI: 0.92–13.97; P = 0.073. Heparin at anticoagulant doses was used in 70.73% of patients before performing CTPA.Conclusion: Among patients presenting pulmonary deterioration after hospitalisation for non‐critical COVID‐19, the prevalence of APE is high. Traditional diagnostic tools to identify high APE pre‐test probability patients do not seem to be clinically useful. These results support the use of a high index of suspicion for performing CTPA to exclude or confirm APE as the most appropriate diagnostic approach in this clinical setting.


  • Open Access

    Acute pulmonary embolism in patients presenting pulmonary deterioration after admission to internal medicine wards for non-critical COVID-19.

    by Hernan Polo Friz, Elia Gelfi, Annalisa Orenti, Elena Motto, Laura Primitz, Tino Donzelli, Marcello Intotero, Paolo Scarpazza, Giuseppe Vighi, Claudio Cimminiello, et al.

    INTRODUCTION. Emerging evidence associates COVID-19 to an increased risk of acute pulmonary embolism (APE). The present study aimed to assess the prevalence of APE in patients admitted to internal medicine department wards for non-critical COVID-19 who presented clinical deterioration, and to investigate the association of clinical and biochemical variables with a confirmed diagnosis of APE in these subjects. METHODS. All consecutive patients admitted to the internal medicine department of a general hospital with a diagnosis of non-critical COVID-19, who performed a Computer Tomography Pulmonary Angiography(CTPA) for respiratory deterioration in April 2020, were included in this retrospective cohort study. RESULTS. Study populations: 41 subjects, median(IRQ) age: 71.7(63-76) years, CPTA confirmed APE=8(19.51%,CI95%:8.82%-34.87%). Among patients with and without APE, no significant differences were found with regards symptoms, comorbidities, treatment, Wells score and outcomes. The optimal cut-off value of D-dimer for predicting APE was 2454 ng/mL, sensitivity(CI95%):63(24-91), specificity:73(54-87), Positive Predictive Value:36(13-65), Negative Predictive Value: 89(71-98) and AUC:0.62(0.38-0.85). The standard and age-adjusted D-dimer cut-offs, and the Wells score > 2 did not associate with confirmed APE, albeit a cut-off value of D-dimer=2454 ng/mL showed an RR:3.21;CI95%:0.92-13.97;p=0.073.CONCLUSION. Among patients presenting pulmonary deterioration after admission to internal medicine wards for non-critical COVID-19, the prevalence of APE was high. The traditional diagnostic tools to identify high APE pre-test probability patients does not seem to be clinically useful. These results support the use of a low threshold of suspicion for performing CTPA to exclude or confirm APE as the most appropriate diagnostic approach in this clinical setting.

  • A survey on the views and attitudes of Italian physicians regarding the prophylaxis and treatment of venous thromboembolism

    by Walter Ageno, Giovanni Di Minno, Giancarlo Agnelli, Claudio Cimminiello, Davide Imberti, Hernan Polo Friz, Paolo Prandoni, Francesco Scaglione

  • Open Access

    Predictors of medium- and long-term mortality in elderly patients with acute pulmonary embolism

    by Hernan Polo Friz, Annalisa Orenti, Elia Gelfi, Elena Motto, Laura Primitz, Luca Cavalieri D’oRo, Cristina Giannattasio, Giuseppe Vighi, Claudio Cimminiello, Patrizia Boracchi


  • Short and long-term mortality in elderly patients with suspected not confirmed pulmonary embolism

    by Hernan Polo Friz, Annalisa Orenti, Mattia Brambilla, Alessandro Caleffi, Valentina Pezzetti, Luca Cavalieri D'ORo, Cristina Giannattasio, Giuseppe Vighi, Claudio Cimminiello, Patrizia Boracchi


  • Comorbidity burden conditions the prognostic performance of D-dimer in elderly patients with acute pulmonary embolism

    by Hernan Polo Friz, Valentina Pezzetti, Annalisa Orenti, Alessandro Caleffi, Valeria Corno, Chiara Crivellari, Francesco Petri, Melisa Polo Friz, Veronica Punzi, Daniela Teruzzi, et al.


  • Open Access

    Antithrombotic therapy for venous thromboembolism in patients with cancer: expert guidance

    by Davide Imberti, Claudio Cimminiello, Marcello Di Nisio, Marco Marietta, Hernan Polo Friz, Walter Ageno

    Introduction: Most of the current clinical guidelines recommend the use of Low-Molecular-Weight Heparins (LMWHs) for cancer-associated thrombosis (CAT). The Hokusai VTE-cancer trial reported the first results of a direct comparison between a direct oral anticoagulant (DOAC), edoxaban, and LMWH in this setting. Areas covered: This review aims to critically appraise the currently available evidence on the efficacy and safety of anticoagulant agents for the long-term treatment of CAT and to provide an expert opinion and guidance in this field. Expert opinion: Based on the available evidence, DOACs represent a valid alternative to LMWH for the treatment of CAT for the majority of patients with active cancer. Currently, most solid evidence comes from the Hokusai VTE-cancer study, which showed that edoxaban is non-inferior to the LMWH dalteparin, with a trend toward fewer recurrent venous thromboembolic events, but with more major bleeding events. Similar findings were reported with rivaroxaban, although the study was not sufficiently powered to allow definitive conclusions. The majority of bleeding events occurred in the upper gastrointestinal tract and in patients with gastrointestinal cancer. Thus, LMWH remains the preferred option for patients with gastrointestinal cancer. Additional studies aimed to confirm these findings with other DOACs are now warranted.


  • Simultaneous validation of the SunTech CT40 automated blood pressure measurement device by the 1993 British Hypertension Society protocol and the Association for the Advancement of Medical Instrumentation/International Organization for Standardization 81060-2

    by Hernan Polo Friz, Veronica Punzi, Francesco Petri, Riccardo Orlandi, Daniele Maggiolini, Melisa Polo Friz, Laura Primitz, Giuseppe Vighi

    This study aimed to perform a simultaneous, third-party, independent validation of the oscillometric SunTech CT40 device for blood pressure (BP) measurement, according to the 1993 protocol of the British Hypertension Society and the standard of the Association for the Advancement of Medical Instrumentation (AAMI)/the International Organization for Standardization (ISO) 81060-2:2013. Patient recruitment, study procedures, and data analysis followed the recommendations stated by the protocols. The study was approved by the institutional review board. A total of 94 participants were included, 52 (55.3%) women, mean±SD age: 63.1±18.0 years, mean±SD arm circumference: 35.0±9.0 cm. The average of observers’ entry BPs was 146.9±37.2 mmHg for systolic blood pressure (SBP) and 82.2±22.1 mmHg for diastolic blood pressure (DBP). Differences between the standard measurement and the test device within 5, 10, and 15 mmHg, for the better observer, were 79.4, 96.5, and 100.0% for SBP and 82.6, 97.5, and 100.0% for DBP, respectively. The mean±SD differences between the readings obtained using the test device and those obtained by the observers (AAMI/ISO 81060-2:2013 standard criterion 1) were 0.3±5.0 mmHg (SBP) and −0.8±4.3 mmHg (DBP), and the mean±SD differences between average of reference readings and average of test device readings in each patient (criterion 2) were 0.3±3.9 and −0.8±3.5 mmHg for SBP and DBP, respectively. The CT40 BP device achieved A/A grade of the British Hypertension Society protocol and fulfilled the requirements (criteria 1 and 2) of the AAMI/ISO standard. CT40 can be recommended for BP measurement in adults.


  • Top Cited Papers
    Open Access

    What hinders the uptake of computerized decision support systems in hospitals? A qualitative study and framework for implementation

    by Elisa G. Liberati, Francesca Ruggiero, Laura Galuppo, Mara Gorli, Marien González-Lorenzo, Marco Maraldi, Pietro Ruggieri, Hernan Polo Friz, Giuseppe Scaratti, Koren H. Kwag, et al.

    Advanced Computerized Decision Support Systems (CDSSs) assist clinicians in their decision-making process, generating recommendations based on up-to-date scientific evidence. Although this technology has the potential to improve the quality of patient care, its mere provision does not guarantee uptake: even where CDSSs are available, clinicians often fail to adopt their recommendations. This study examines the barriers and facilitators to the uptake of an evidence-based CDSS as perceived by diverse health professionals in hospitals at different stages of CDSS adoption. Qualitative study conducted as part of a series of randomized controlled trials of CDSSs. The sample includes two hospitals using a CDSS and two hospitals that aim to adopt a CDSS in the future. We interviewed physicians, nurses, information technology staff, and members of the boards of directors (n = 30). We used a constant comparative approach to develop a framework for guiding implementation. We identified six clusters of experiences of, and attitudes towards CDSSs, which we label as “positions.” The six positions represent a gradient of acquisition of control over CDSSs (from low to high) and are characterized by different types of barriers to CDSS uptake. The most severe barriers (prevalent in the first positions) include clinicians’ perception that the CDSSs may reduce their professional autonomy or may be used against them in the event of medical-legal controversies. Moving towards the last positions, these barriers are substituted by technical and usability problems related to the technology interface. When all barriers are overcome, CDSSs are perceived as a working tool at the service of its users, integrating clinicians’ reasoning and fostering organizational learning. Barriers and facilitators to the use of CDSSs are dynamic and may exist prior to their introduction in clinical contexts; providing a static list of obstacles and facilitators, irrespective of the specific implementation phase and context, may not be sufficient or useful to facilitate uptake. Factors such as clinicians’ attitudes towards scientific evidences and guidelines, the quality of inter-disciplinary relationships, and an organizational ethos of transparency and accountability need to be considered when exploring the readiness of a hospital to adopt CDSSs.